€0.00
-50.00%
Compare
NNeovacs vs Abivax SAANNeovacs vs NanobiotixNNNeovacs vs Abionyx Pharma S.AANNeovacs vs Innate Pharma S.AINNeovacs vs Maat Pharma S.A.C.AMNNeovacs vs CAC 40 | MarketC

TL;DR: Financial Overview - Revenue, Profits & Key Metrics

Income Metrics

Balance Sheet Metrics

Total Assets 22.1M
Total Liabilities 4.0M
Shareholders Equity 18.1M
Debt to Equity 0.22

Cash Flow Metrics

Revenue & Profitability Trend

Annual Income Flow i

Neovacs Income Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Revenue i 366.3K 534.3K 2.5K 22.6K 30.1K
Cost of Goods Sold i 323.9K 504.1K 577.4K 484.9K 120.0K
Gross Profit i 42.4K 30.2K -574.9K -462.3K -89.9K
Gross Margin % i 11.6% 5.6% -23,192.0% -2,046.1% -298.1%
Operating Expenses
Research & Development i - - - - -
Selling, General & Administrative i - - - 4.1M 1.6M
Other Operating Expenses i 3.0M 3.7M 3.8M 4.3M 1.7M
Total Operating Expenses i 3.0M 3.7M 3.8M 8.4M 3.3M
Operating Income i -13.7M -12.3M -6.8M -7.9M -3.6M
Operating Margin % i -3,731.8% -2,305.1% -273,345.0% -34,922.6% -12,012.7%
Non-Operating Items
Interest Income i 1.1M 1.5M 1.2M 45.2K 3.3K
Interest Expense i 0 0 0 364 844
Other Non-Operating Income - - - - -
Pre-tax Income i -33.9M -9.6M -4.3M -12.5M -6.7M
Income Tax i -1.0M -876.8K -797.4K -641.0K -541.5K
Effective Tax Rate % i 0.0% 0.0% 0.0% 0.0% 0.0%
Net Income i -32.9M -8.7M -3.5M -11.8M -6.1M
Net Margin % i -8,984.5% -1,636.5% -143,142.5% -52,389.0% -20,379.1%
Key Metrics
EBITDA i -25.1M -3.7M -2.7M -9.5M -5.4M
EPS (Basic) i €-221.36 €-249,812.86 €-1,182,834.33 €-47,731.06 €-767,832.63
EPS (Diluted) i €-221.36 €-249,812.86 €-1,182,834.33 €-47,731.06 €-767,832.63
Basic Shares Outstanding i 269590 35 3 248 8
Diluted Shares Outstanding i 269590 35 3 248 8

Income Statement Trend

Neovacs Balance Sheet From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Assets
Current Assets
Cash & Equivalents i 435.4K 887.1K 43.1K 16.2M 10.1M
Short-term Investments i 8 - 6.7M 16.8M -
Accounts Receivable i 305.8K 572.9K 6.6K 5.3K 75.0K
Inventory i - - - - -
Other Current Assets 41.7K 107.2K 30.1K 145 188
Total Current Assets i 2.5M 3.8M 9.1M 34.8M 13.1M
Non-Current Assets
Property, Plant & Equipment i 193.7K 79.5K 119.7K 98.6K 127.6K
Goodwill i 441 876 2.6K 1.3K 0
Intangible Assets i 441 876 2.6K 1.3K -
Long-term Investments - - - - -
Other Non-Current Assets - - -1 1 -1
Total Non-Current Assets i 19.6M 48.7M 46.2M 13.8M 435.1K
Total Assets i 22.1M 52.6M 55.3M 48.6M 13.5M
Liabilities
Current Liabilities
Accounts Payable i 2.3M 2.0M 1.9M 1.3M 1.3M
Short-term Debt i 230.4K 586 4.0K 5.0K 1.5K
Current Portion of Long-term Debt - - - - -
Other Current Liabilities 205.1K 32.4K 514.8K 1.4M 111.8K
Total Current Liabilities i 4.0M 3.1M 3.9M 3.6M 2.1M
Non-Current Liabilities
Long-term Debt i - 650.0K 1.2M 1.0M 310.0K
Deferred Tax Liabilities i - - - - -
Other Non-Current Liabilities - - - 1 1
Total Non-Current Liabilities i 6.9K 651.8K 1.2M 1.0M 392.0K
Total Liabilities i 4.0M 3.7M 5.1M 4.7M 2.5M
Equity
Common Stock i 174.5K 351.7K 121.4K 2.0M 675.2K
Retained Earnings i -60.3M -94.6M -89.6M -93.2M -94.0M
Treasury Stock i - - - - -
Other Equity - - - - -
Total Shareholders Equity i 18.1M 48.8M 50.2M 43.9M 11.0M
Key Metrics
Total Debt i 230.4K 650.6K 1.2M 1.0M 311.5K
Working Capital i -1.5M 772.7K 5.2M 31.2M 11.0M

Balance Sheet Composition

Neovacs Cash Flow Statement From 2020 to 2024

Metric 2024 2023 2022 2021 2020
Operating Activities
Net Income i -32.9M -8.7M -3.5M -11.8M -6.1M
Depreciation & Amortization i - - - - -
Stock-Based Compensation i - - - - -
Working Capital Changes i 0 0 0 0 0
Operating Cash Flow i -12.5M -8.7M -3.5M -11.8M -6.1M
Investing Activities
Capital Expenditures i -79.7K -203.4K -152.7K -348.9K -206.9K
Acquisitions i - - - - -
Investment Purchases i -493.4K -13.7M -34.0M -18.5M -15.8K
Investment Sales i 2.0M 2.9M 2.6M 68.4K 0
Investing Cash Flow i 1.5M -11.1M -31.6M -18.8M -222.7K
Financing Activities
Share Repurchases i - - - - -
Dividends Paid i - - - - -
Debt Issuance i 1.1M 6.2M 9.0M 46.8M 14.0M
Debt Repayment i -1.5M -5.0M -8.8M -46.2M -13.8M
Financing Cash Flow i 1.7M 6.8M 10.0M 51.7M 14.6M
Free Cash Flow i -3.7M -2.1M -4.6M -10.3M -5.9M
Net Change in Cash i -9.4M -13.0M -25.1M 21.1M 8.3M

Cash Flow Trend

Neovacs Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 0.00
Forward P/E 0.00
Price to Book 0.00
Price to Sales 0.00
PEG Ratio 0.00

Profitability Ratios

Profit Margin 11.58%
Operating Margin -1,683.64%
Return on Equity -23.23%
Return on Assets -10.66%

Financial Health

Current Ratio 0.67
Debt to Equity 0.90
Beta 106.29

Per Share Data

EPS (TTM) €-221.36
Book Value per Share €39.63
Revenue per Share €0.42

Peer Financial Comparison

Company Market Cap P/E Ratio P/B Ratio ROE Profit Margin Debt/Equity
ALNEV 190 0.00 0.00 -23.23% 11.58% 0.90
Abivax SA 7.6B -19.88 16.56 -135.58% 0.00% 7.05
Nanobiotix 1.4B - - 28.36% -73.52% -1.13
Abionyx Pharma S.A 128.4M -22.75 23.18 -123.01% -134.15% 0.84
Innate Pharma S.A 108.3M -2.05 - 226.58% 0.00% -1.04
Maat Pharma S.A.C.A 99.9M -2.47 9.69 -511.92% 61.13% 969.43
Nippun Rana

Nippun Rana

Chasing the market trend!

Hi, I’m Nippun, a tech enthusiast from Haryana, India. I have been coding since 2010 and using my coding skills in the share market since 2020. I have been coding scripts in Pinescript that work on Tradingview app/web. I love learning about new technology and applying it to solve real-world problems. Coding and share-market are my passions, and I enjoy finding and fixing bugs in code. I aim to share my skill set and experience that can positively impact society. Feel free to connect with me, an...

Financial data is updated regularly. All figures are in the company's reporting currency.